Drug Development

Listings
  • How an Organization can remain Compliant with these Regulations

    How an Organization can remain Compliant with these Regulations

    Drug Development Fremont (California) April 19, 2018 Free

    Overview: Among those educational requirements are a course in Introductory GMP upon employment at a pharmaceutical company, and annual refresher GMP training. Why should you Attend: The laws that govern Good Manufacturing Practices (GMP) are a corne...

  • FDA Concepts for Medical Device Companies - Regulations, Myths, Challenges, and Best Practices

    FDA Concepts for Medical Device Companies - Regulations, Myths, Challenges, and Best Practices

    Drug Development Baltimore (MD ) October 26, 2016 Free

    Overview: This seminar will show you how to structure and optimize your QMS. It all starts with Management Responsibility and a commitment to quality. We'll discuss the concepts of management responsibility, a culture of quality, and continuous impro...

  • Batch Record Review and Product Release - 2017

    Batch Record Review and Product Release - 2017

    Drug Development Fremont (California) August 14, 2017 Free

    Overview: A strong batch record review system is essential in order to properly document all critical processing parameters that go along with the production and manufacture of pharmaceuticals, biologics, medical devices, etc. Why should you Attend: ...

  • Guidance on Software and Device Changes and the 510(k)

    Guidance on Software and Device Changes and the 510(k)

    Drug Development Fremont (California) August 14, 2017 Free

    Overview: The first guidance document clarifies key terms and provides insight as to how a risk assessment can help medical device manufacturers to evaluate whether a new 510(k) is required. Why should you Attend: Anyone who is involved in software a...

  • Act for Transportation and Logistics Professionals

    Act for Transportation and Logistics Professionals

    Drug Development Fremont (California) November 27, 2017 Free

    Overview: The FSMA is paradigm shift that moves the focus from food inspections to preventative measures and process compliance. Why should you Attend: Specific provisions of the FSMA that impacts transportation and 3rd party logistics providers Sani...

  • The Value of a Human Factors Program

    The Value of a Human Factors Program

    Drug Development Fremont (California) November 27, 2017 Free

    Overview: This webinar will explain the implementation of ISO 62366 and the regulatory expectations discussed in the 2016 FDA Guidance for a compliant human factors/ usability program. Why should you Attend: This year FDA published their priority lis...

  • Anti-CD22 (clone 5E8)-SMCC-DM1 ADC

    Anti-CD22 (clone 5E8)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 5E8) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within t...

  • Anti-CD22 (clone 7A2)-SMCC-DM1 ADC

    Anti-CD22 (clone 7A2)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 7A2) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within t...

  • Anti-CD22 (clone 10F4v1)-SMCC-DM1 ADC

    Anti-CD22 (clone 10F4v1)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v1) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...

  • Anti-CD22 (clone 10F4v2)-SMCC-DM1 ADC

    Anti-CD22 (clone 10F4v2)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v2) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...

  • Anti-CD22 (clone 10F4v2)-Mc-MMAF ADC

    Anti-CD22 (clone 10F4v2)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v2) conjugated via a Mc linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...

  • Anti-CD22 (clone 10F4v3)-SMCC-DM1 ADC

    Anti-CD22 (clone 10F4v3)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 13, 2017 Check with publisher

    This ADC product is comprised of an anti-CD22 monoclonal antibody (clone 10F4v3) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...